Empower Pharmacy for cash-pay clinics: how the economics work

Landed cost at Empower is the per-vial compounding cost established in the clinic agreement plus shipping fees. Empower offers ground and overnight shipping with costs that depend on order size and carrier. For cash-pay clinics, the economic evaluation of Empower is less about whether rates are competitive and more about whether the all-in cost per vial is clearly visible before a patient is quoted. Because Empower is a direct compounder rather than a platform intermediary, there is no intermediary markup layer — the cost reflects Empower's compounding pricing. The key question is how that pricing is structured and whether it stays stable across high-volume refill cycles.

For GLP-1 programs specifically — semaglutide and tirzepatide at various titration points — the formulary includes multiple formulations and strengths. Cash-pay clinics prescribing titration-based weight loss programs need to confirm Empower's per-vial cost at each titration level, since patient program pricing often varies by dose. Because these rates are not published publicly, the evaluation requires an active clinic agreement conversation.

Fizy Health takes a pass-through approach to the same cash-pay problem. It shows resolved 503A per-vial cost on every catalog and cart line before checkout, with a disclosed facilitation fee at payment — so the clinic sees the landed cost on semaglutide, tirzepatide, testosterone, or peptides before a patient is quoted and before the order is placed. There is no pre-agreement required to see pricing; the cost is in the catalog.

The operations side works similarly: one clinic cart batches the refill day across assigned 503A partners, and cart validation catches SIG and licensure issues before payment so rejected orders do not eat into margin. For a cash-pay clinic, the combined effect is margin visible before the consult and fewer surprises that quietly erode the spread between patient price and actual cost.